SeaStar Medical Holding Corporation (ICU)
| Market Cap | 17.21M -6.0% |
| Revenue (ttm) | 1.23M +814.1% |
| Net Income | -12.15M |
| EPS | -5.86 |
| Shares Out | 3.99M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 423,330 |
| Open | 3.410 |
| Previous Close | 3.560 |
| Day's Range | 3.370 - 4.550 |
| 52-Week Range | 2.070 - 14.713 |
| Beta | -1.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | May 13, 2026 |
About ICU
SeaStar Medical Holding Corporation, a commercial-stage medical device company, develops a proprietary platform therapy to reduce the consequences of hyperinflammation on vital organs in the United States. The company offers the selective cytopheretic device (SCD), which is a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation; and QUELIMMUNE, an SCD therapy for pediatric patients with acute kidney injury (AKI) due to sepsis. It also develops NEUTRALIZE-AKI, a... [Read more]
Financial Performance
In 2025, SeaStar Medical Holding's revenue was $1.23 million, an increase of 814.07% compared to the previous year's $135,000. Losses were -$12.15 million, -51.07% less than in 2024.
Financial StatementsNews
SeaStar Medical Showcases New Positive Data from the QUELIMMUNE SAVE Registry and an Analysis of the Unique Immunomodulatory Mechanism of the SCD Therapy at AKI & CRRT 2026
Results from pediatric patients in the SAVE Registry shows no device-related adverse events or immunosuppression and continued strong survival data
SeaStar Medical Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates
Added top-rated children's hospitals to QUELIMMUNE™ pediatric Acute Kidney Injury (AKI) customer base Completed enrollment in FDA-mandated QUELIMMUNE SAVE Post-Marketing Registry Exceeded 50% enrollme...
SeaStar Medical to Report Fourth Quarter and Year-End 2025 Financial Results on March 25, 2026
DENVER, March 18, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facin...
SeaStar Medical to Present at the Life Sciences Investor Forum on March 11th
The Company invites individual and institutional investors, as well as advisors and analysts with an interest in the life sciences sector, to attend live, interactive presentations at VirtualInvestorC...
SeaStar Medical Announces Completion of FDA Enrollment Requirement for SAVE Surveillance Registry Evaluating QUELIMMUNE Safety for Pediatric AKI
Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements Completion of enrollment marks a key milestone toward satisfying FDA post-approval requirements
SeaStar Medical Announces Publication in Pediatric Nephrology of Positive Real-World Experience for QUELIMMUNE™ (SCD-PED) Therapy in Pediatric Acute Kidney Injury (AKI)
Strong survival data extending to 90 days Real-world experience shows results consistent with clinical trial data Favorable safety profile – no device-related adverse events DENVER, Feb. 09, 2026 (GLO...
SeaStar Medical to Present at Upcoming Noble Capital Markets Emerging Growth Virtual Equity Conference
DENVER, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing...
SeaStar Medical Announces 2026 Milestones
Drive adoption of QUELIMMUNE for ultra-rare pediatric AKI, expanding revenue and doubling the customer base Advance SeaStar Medical's first-in-class SCD therapy for the adult AKI indication – a potent...
SeaStar Medical to Present at Upcoming Biotech Showcase 2026 Investor Conference
DENVER, Jan. 06, 2026 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing...
SeaStar Medical Announces 1-for-10 Reverse Split
DENVER, Dec. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing...
SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI
FDA lowers surveillance requirement to 50 patients from 300 patients in original HDE approval based on assessment of first 21 SAVE Surveillance Registry patients
SeaStar Medical to Present at Upcoming NobleCon21 Investor Conference
DENVER, Nov. 20, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing...
SeaStar Medical Announces Appointment of Michael Messinger as CFO
DENVER, Nov. 17, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing...
SeaStar Medical Reports Third Quarter 2025 Financial Results and Provides Business Updates
Business highlights include: Three new top-rated children's hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute Kidney Injury (AKI) Commercial use of QUELIMMUNE therapy demonstrates posi...
SeaStar Medical to Report Third Quarter Financial Results on November 13, 2025
DENVER, Nov. 05, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing...
SeaStar Medical Reports Positive Early Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) at the 5th International Symposium on Acute Kidney Injury in Children
Data show results consistent with clinical trial experience A high level of safety – no device-related adverse events Strong survival data extending to 90 days
SeaStar Medical Reports DSMB Recommendation to Continue the NEUTRALIZE-AKI Pivotal Trial in Adult Acute Kidney Injury
Independent DSMB reports zero device-related safety issues Supports potential clinical benefit Trial sample size re-estimated to strengthen statistical power
SeaStar Medical to Present Early SAVE Registry Data of QUELIMMUNE in Pediatric Acute Kidney Injury at the 5th International Symposium on Acute Kidney Injury in Children
DENVER, Sept. 23, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today that preliminary results from the SAVE Surveillance...
SeaStar Medical to Participate in the HC Wainwright 27th Annual Global Investment Conference
DENVER, Sept. 04, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facin...
SeaStar Medical Announces Newly Published QUELIMMUNE Health Economic Study Projecting Significantly Reduced Health Care Costs in the Treatment of Pediatric AKI due to Estimated Shorter Hospital Stays and Increased Survival
DENVER, Sept. 02, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facin...
SeaStar Medical Reports Second Quarter 2025 Financial Results and Provides Business Updates
Business highlights include: Adult NEUTRALIZE-AKI trial enrolls 31 new patients, now over 60% enrolled Three new top-rated children's hospitals adopt QUELIMMUNE therapy for ultra-rare pediatric Acute ...
SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025
DENVER, Aug. 07, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing...
SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)
Trial now over 60% enrolled with 125 of 200 anticipated patients Recent new site activation brings total clinical trial sites to 16 Interim analysis of first 100 patients remains on track for 3Q 2025 ...
SeaStar Medical Announces $4.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
DENVER, July 31, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing...
SeaStar Medical Reports Positive Results for QUELIMMUNE Therapy in Pediatric Acute Kidney Injury (AKI) from the First 20 SAVE Surveillance Registry Patients
DENVER, July 22, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today positive preliminary results from the SAVE Surveilla...